-+ 0.00%
-+ 0.00%
-+ 0.00%

Evogene, ELEO collaborate to develop oral small-molecule PCSK9 inhibitors for hyperlipidemia

PUBT·07/22/2026 12:02:49
Listen to the news
Evogene, ELEO collaborate to develop oral small-molecule PCSK9 inhibitors for hyperlipidemia
  • Evogene entered a scientific collaboration with South Korea’s Eleo to discover oral small-molecule inhibitors targeting the PCSK9 pathway for hyperlipidemia.
  • Evogene will use its ChemPass AI platform to design and optimize candidates; Eleo will run biological validation and screening to advance leads toward preclinical work.
  • The partners will assess later-stage options, including licensing and collaborations with global drugmakers.
  • The companies cited a PCSK9 inhibitor market forecast to grow from about $4.4 billion in 2025 to more than $23 billion by 2035.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN10034) on July 22, 2026, and is solely responsible for the information contained therein.